US OptionsDetailed Quotes

SYK240719C380000

Watchlist

0.09
0.000.00%

15min DelayClose Jul 17 15:59 ET

0.00High0.00Low

Stryker Corp Stock Discussion

Nicholas Gilchrist3

May 15 07:40

$Stryker Corp(SYK.US)$

Nicholas Gilchrist3

May 15 07:40

$Stryker Corp(SYK.US)$

Moomoo AI

Feb 9 04:58

The recent insider sale of Stryker shares at the current price is viewed negatively. However, high insider ownership is seen positively, suggesting management's consideration for shareholders. Yet, the absence of insider buying over the past year is worrisome.

Don't Ignore The Insider Selling In Stryker

Moomoo AI

Feb 2 05:31

The EPS decline doesn't align with share price changes, indicating other factors. Management might be prioritizing revenue growth over EPS. The company's recent performance improvement suggests potential business momentum.

Despite the Downward Trend in Earnings at Stryker (NYSE:SYK) the Stock Climbs 9.4%, Bringing Five-year Gains to 97%

ColumnsStryker Shares Surge 6.3% as 2024 Outlook, Q4 Results Beat Estimates

$Stryker Corp(SYK.US)$ shares advanced 6.6% after the company gave a better-than-expected outlook for 2024 and delivered an earnings beat, prompting analysts to upgrade the stock.
The company sees 2024 adjusted earnings to reach $11.70 to $12 a share, according to its press release. That's higher than the $11.54 estimate of analysts polled by Capital IQ, according to MT Newswires.
"Based on our momentum for 2023, strong proce...

Editor's Picks: Community Q4 earnings insights & highlights

Moomoo AI

Dec 31, 2023 06:39

Investors feel Stryker's high P/E ratio is justified due to its favorable earnings outlook. Their optimism on consistent earnings growth maintains the elevated ratio as expectations for a drop in earnings are low. A significant change in conditions could alter this supportive investor sentiment.

Investors Still Waiting For A Pull Back In Stryker Corporation (NYSE:SYK)

Analysts Notebook

Dec 27, 2023 04:18

ColumnsBiotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index(.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...

Moomoo AI

Dec 24, 2023 13:28

Baird advocates medtech companies such as Alcon, Stryker, and Cooper due to product and pricing strengths. Belief is strong in Alcon's 2024 margin possibilities, Stryker's premium pricing and predicted robust orthopedic demand, and projected revenue growth for Boston Scientific and Axonics.

Baird Names Top Medtech Picks for 2024; Bullish on Alcon, Axonics

Moomoo AI

Dec 20, 2023 07:21

Stryker has proven its ability to reinvest capital at good rates of return, and with consistency in returns, it can potentially yield favorable share price returns. Despite some risks, this stock is worth further exploration.

Slowing Rates Of Return At Stryker (NYSE:SYK) Leave Little Room For Excitement

No comment yet